Total-body PET scan using FDA-approved tracers for prostate or NET cancer
Part of Cancer, Kidney & urinary, Skin clinical trials.
This pilot study tests a total-body PET scan with approved tracer medicines to help detect cancer spread in people with suspected metastatic prostate cancer or certain neuroendocrine tumors (NETs). You may be able to join if recent scans already suggest metastasis and you can safely complete the scan timing and positioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old
- Your most recent scan (CT/MRI/bone scan/fluciclovine or DOTATATE PET/CT) suggests cancer spread and was done within the required time window
- If you have prostate cancer, you’re being checked for suspected metastatic disease
- If you have a NET, your tumor must be somatostatin-receptor positive on a prior DOTATATE PET/CT
- You cannot be pregnant or breastfeeding
- You must be able to lie flat (on your back) for up to 90 minutes at scan timepoints and manage claustrophobia
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
This trial uses special PET imaging to see where progressive prostate cancer is in the body—one tracer to look at general sugar use and one designed to detect testosterone-related activity. It may help doctors better map cancer spread so future treatment planning can be more targeted.
This trial compares two types of PET scans—one using a new tracer called [18F]F-PSMA-N5 and another using an existing tracer called [68Ga]Ga-PSMA-11—to see which is better at finding prostate cancer, including early signs of recurrence. If you have or are suspected of having prostate cancer, this study may help determine how advanced the disease is.
This study compares a new imaging agent (Al18F-NOTA-LM3) with two existing ones (68Ga-DOTATATE and 68Ga-NODAGA-LM3) during PET/CT scans to see if it's better at finding well-differentiated neuroendocrine tumors. Participating may help improve how these tumors are detected.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.